Posted February 28, 2017
In a clinical trial sponsored by the National Institute of Child Health in Hungary in collaboration with Merck, researchers indicated in 2014 they were going to test the original 4-valent Gardasil vaccine to treat recurrent respiratory papillomatosis (RRP), a rare disease in children caused by HPV types 6 and 11, which also cause genital warts. The study was designed to enroll children as young as 1 year old with RRP and administer three doses of the HPV vaccine to “assess response to vaccination.”8 The trial was first registered with the U.S. government’s clinical trial database in November, 2013, with an estimated completion date of February, 2017. Read more.